Physician profile
Jo Ann Pullen
NPI 1225005663
$3,465.39
in general payments reported to CMS, 2019-2025
28 companies · $511 in 2025
The $511 reported for 2025 was more than what 79% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $371 · 2021: $420 · 2022: $456 · 2023: $725 · 2024: $312 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.06 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Bayer Healthcare Pharmaceuticals INC. | $537.80 | 2021-2025 | |
| Avanir Pharmaceuticals, INC. | $451.63 | 2019-2022 | |
| Lilly USA, LLC | $247.10 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Arbor Pharmaceuticals, INC. | $196.42 | 2020-2022 | |
| Glaxosmithkline, LLC. | $165.69 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $153.52 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $132.82 | 2019-2020 | |
| Novo Nordisk INC | $121.37 | 2023-2024 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $94.21 | 2025 | |
| Astellas Pharma US INC | $79.83 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $77.72 | 2023 | Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.12 | 2023-2025 | Jardiance |
| Pfizer INC. | $70.60 | 2019-2023 | |
| Exact Sciences Corporation | $54.49 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2020-2024 | Eliquis |
| Radius Health, INC. | $34.08 | 2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $32.47 | 2025 | Voquezna |
| Almatica Pharma LLC | $30.91 | 2021 | |
| Amgen INC. | $25.65 | 2024 | Otezla, Repatha |
| Lundbeck LLC | $24.79 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $21.71 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $19.97 | 2019 | |
| Cipher Pharmaceuticals US LLC | $16.65 | 2025 | Natroba, Spinosad |
| Hikma Pharmaceuticals USA | $15.88 | 2021 | |
| Redhill Biopharma INC. | $14.50 | 2021 | |
| Allergan, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jo Ann Pullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.